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Abstract. The use of 5-aminolevulinic acid to induce
endogenous porphyrins for the purpose of detection of
epithelial cancers is being studied extensively in many
centres around the world. The challenge is to prepare an
efficacious formulation of 5-ALA for the purpose of cancer
detection. In this study, we compared two formulations of
·:topical 5-ALA applications with intravenous administration
in NPC/CNE-2 xenografts on balb/c nude mice. One of the
formulations was a gantrez muco-adhesive patch and the
9ther was a polyvinyl-pyrolidone muco-adhesive patch. The
1
t Karl Storz fluorescence endoscopy system was used to obtain
f macroscopic fluorescence images. Microscopic fluorescence
: imaging was done by laser confocal microscopy. The
macroscopic images were further analysed for fluorescence
intensity distribution. It was found that between the two
; formulations of topical application of 5-ALA; there was very
· little difference in the fluorescence biodistribution. When the
topical applications were compared with the intravenous
administration, the tumour to normal differential in biodistribution was significantly higher with the topical application
compared to the intravenous application.

.
I

Introduction

1

.! The use of endogenous protoporphyrin IX (PpIX) as a
: photosensitizer to diagnose certain superficial cancers is
· under extensive study in many centres around the world.
5-Aminolevulinic acid (5-ALA) is a precursor in the heme
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biosynthetic pathway of nucleated cells. It is metabolized
by certain endogenous enzymes to produce PpIX, which is
an endogenous photosensitizer. PpIX is an intermediate
by-product in the heme biosynthetic pathway (1). Survival of
mammalian cells is crucially dependent upon the biosynthesis
and metabolism of porphyrins (2). All mammalian nucleated
cells have the capacity to synthesize heme. PpIX being the
immediate precursor of heme will also be synthesized in
equal amounts. However, a tight feedback loop control
ensures that only a very small amount of PpIX is left at any
one time (3). Accumulation of the endogenous porphyrins
only happens under abnormal conditions such as in malignant
or pre-malignant cell transformation. PpIX preferentially
accumulates in tumour cells due to changes in the activity of
two main enzymes, porphobilinogen deaminase (PBG) and
ferrochelatase (FC) (4-6). In tumour cells, while the activity
of PBG is increased, the activity of FC is decreased resulting
in the build up of PpIX. In normal cells, FC catalyses the
conversion of photosensitive PpIX to heme, which is not
photosensitive. It chelates the Fe2+ into the porphyrin ring
structure. The over production of PpIX can also be induced
by the administration of exogenous 5-ALA or ALA esters
(topically or intravenously). While 5-ALA is hydrophilic,
which is a limitation as it restricts its penetration through
cellular membranes; its ester derivatives have been developed
to be of increased lipophilicity.
PpIX is a well-known photosensitizer that yields sufficient
singlet oxygen when activated by light of appropriate
wavelength and intensity. 5-ALA is already in use in many
centres for photodynamic diagnosis (PDD) and photodynamic
therapy (PDT) in various superficial diseases such as actinic
keratosis, basal cell carcinoma and squamous cell carcinoma.
5-ALA induced PpIX is also highly fluorescent. Upon
activation with blue/violet light, PpIX fluoresces in the red .
5-ALA is in use for the detection of neoplastic urothelial
lesions, early stage lung cancer, cervical dysplasia and
laryngeal neoplasm.
There have only been a few studies conducted with
respect to pharmacokinetics of 5-ALA-induced porphyrins
following topical applications. Most studies have been done
on applications to the skin. It was observed that the normal
looking skin overlaying the tumours constitutes a much
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lower barrier for 5-ALA penetration than the skin overlaying
healthy tissues. It was also found that the 5-ALA induces
more PpIX fluorescence than certain of its esters do.
Systemic uptake is also reported to be high resulting in high
accumulation of PpIX in other vital organs such as the liver,
gut and skin. These studies were compared with intravenous
or intraperitoneal administrations of 5-ALA (7-10). The aim
of this study was to compare the uptake and retention
pharmacokinetics of the topical applications of 5-ALA, in the
form of muco-adhesive patches and intravenous administration.
With the use of macroscopic and microscopic fluorescence
imaging of endogenous PpIX, the optimal selectivity
between tumour and normal regions was determined. Gantrez
and polyvfoylpyrolidone were chosen to prepare the patches
for topical applications, respectively.

tumour was carefully removed to expose the tumour.
Extreme care was taken to minimize bleeding as this can
interfere with the imaging procedure. A white light image of
the tumour was obtained using the Karl Storz fluorescence
endoscopy system (FES). This is to help later in identifying
the tumour and its margins when comparing with the
fluorescence image. The patches were then applied on the
tumour making sure that the patch covers the tumour well
and part of the normal tissue surrounding the tumour. For the
PP muco-adhesive patches, the patch was applied for 30 min
and thl;!n removed. The area was rinsed well with 70%
alcohol to remove any residual 5-ALA. The tumour was
imaged by the FES, at different time points, post patch
application, using filtered blue light at 460 nm. For the GP
muco-aclhesive patches, the patch was left on for I h, before
it was imaged using the endoscopy system.

Materials and methods

Tumour model. CNE-2 is a cell line derived from a poorly
differentiated nasopharyngeal carcinoma in human. It was a
gift from Professor K.M. Hui, Cellular and Molecular
Research, National Cancer Centre, Singapore. The cells
were grown in culture medium RPMI I640 supplemented
with 10% fetal bovine serum (FBS; Hyclone, Logan, UT),
IX L-glutamine, 100 units/ml penicillin and streptomycin
(Gibco) and IX sodium pyruvate in an atmosphere of 5%
C0 2 at 37°C. Once confluent they were washed with IX
phosphate buffered saline and trypsinized with 0.05%
Trypsin-EDTA (Gibco). The cells were then re-suspended in
IX Hanks balanced salt solution. Male Balb/c nude mice, 6-8
weeks old, about 20-25 g were obtained from Animal
Resource Centre of Australia. The trypsinized cells were
implanted subcutaneously into the flanks of the nude mice.
The mice were housed in micro-isolator cages (5 per cage)
fed with filtered air through air vents. Their food, water and
bedding were sterilized. The tumour was allowed to grow
over the next 7-10 days to a size of 5-8 mm in diameter.
5-ALA muco-adhesive patches. In the Gantrez patch series
(GP), S-ALA was dissolved in poly (methyl vinyl ether/maleic
anhydride (Gantrez, ISP, USA)/poly (meth) acrylates (Eudragit,
Rohm Pharma, Germany)/alcohol solution. In the Polyvinyl
pyrolidone patch series (PP), 5-ALA was dissolved in
polyvinyl-pyrolidone (Plasdone, ISP, USA)/alcohol solution.
A low concentration of I mg/cm 2 of 5-ALA and high
concentration of 2.5 mg/cm2 of 5-ALA were made for both
formulations of patches. The solution was then poured onto a
calculated area of polythene sheets and left to dry. The
patches were cut into I .5 cm2 pieces and sealed in bags and
stored for further use. Both formulations have muco-adhesive
properties.
Animal experiments. Three groups of animals were used. One
group was used for the intravenous administration of 5-ALA;
the other two were used for PP and GP applications. For
topical application, IO mice per group were used. The
nude mice were anaesthetized with a cocktail of Hypnorm
(0.3 I5 mg/ml fentanyl citrate and IO mg/ml flaunisone,
Janssen), Dormicum (5 mg/ml midazolam HCl, David Bull
Laboratories) and deionised water. The skin overlaying the

Intravenous administration. 5-ALA was dissolved in 0.9%
sodium chloride solution and the pH was adjusted to 6.5. The
mice were administered with a dose of 250 mg/kg-body
weight by tail vein injections. Ten animals were used for
each time point. They were then kept in darkness. The mice
were imaged at I and 3 h, the skin overlaying the tumour was
removed and the tumours were imaged using the FES. The
mice were sacrificed, the tumours were removed and snapfrozen in liquid nitrogen and stored at -80°C for further··
analysis.
Image analysis. The images thus obtained were analyzed
using the image analysis software, Microimage 4.0. Images
obtained in blue light needed to be further processed to obtain
normalized fluorescence intensity images. The processing
involves contrast enhancement of the original image. This is
followed by hue extraction where the fluorescence colour ;
(red) that is needed is extracted. Following hue extraction,
the thresholding and segmentation of the Area of Interest
(AOI), which is the tumour in this case, was carried out. This
gives us the red-black image. From this we obtained the
relative intensity distribution over the tumour and the normal
regions. Finally, the normalised intensity image, which is a
ratio of the tumour fluorescence to the normal (blue)
background, was obtained.
Microscopic imaging. Cross sectional cryo-sections of the
frozen tumours were obtained by using the Microm Cryostat. The cryo-sections were sandwich sections, which means the
thickness of the sections were in the order of 5-10 µrn/I520 µm/5-10 µm. The thinner sections were stained with
haematoxylin and eosin (H&E). The thicker middle sections
were imaged using the fluorescence laser confocal
microscope (Carl Zeiss LSM510, Germany). An argon ion
laser with a wavelength of 488 nm was used to excite the
PpIX in the tissue and a 590 nm long pass filter was used to
detect the PpIX fluorescence. An untreated tumour was used
as a control and to subtract background fluorescence.
Statistical analysis. Statistical analysis was done using the
SPSS 10.0 statistical package for windows. Analysis was
done by comparing means (ANOVA). The mean difference
was found to be statistically significant (p<0.05).
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Figure 1. (A), White light image obtained by endoscopy system; (B), Red-black image obtained during image processing indicating fluorescent area of
interest; (C), Fluorescence intensity distribution indicating low (green), medium (yellow) and high (red) regions within the tumour; (D), Enhanced
fluorescence image of tumour.
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Figure 2. Normalised fluorescence intensity of tumour versus normal as a
function of time for intravenous administration.
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Results

The normalized intensity for the macroscopic fluorescence
images was obtained by using the Microlmage 4.0. software.
From the series of processed images obtained (GP patch) at
1-3 h post application (Fig. 1) it can be seen clearly that
PpIX is qighly selective to tumourous regions. When the
normalized fluorescence intensities that were obtained
from the tumours were plotted in histograms, both the PP
and the GP patches were found to have tumour fluorescence
increasing with time. The tumour to normal fluorescence
ratio (TIN) also increased correspondingly. For the PP
patches (1 mglcm 2 and 2.5 mglcm 2), by 3 h the TIN ratio
Was almost 2.6 (p<0.05). At 6-h post 5-ALA patch
application, the TIN ratio was 2 (p<0.05). The GP patches
(1 mglcm2 and 2.5 mglcm 2), followed similar patterns as
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Figure 3. (A), Normalised fluorescence intensity of tumour versus normal as a
function of time for 1 mglcm2 PP patch; (B), Normalised fluorescence intensity
of tumour versus normal as a function of time for 2.5 mglcm2 PP application.

the PP patches (Figs. 3 and 4). By 3 h TIN ratio was also high,
almost 2. When 5-ALA was intravenously administered, the
background normal tissue fluorescence was high between
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Figure 4. (A), Normalised fluorescence intensity of tumour versus normal,
as a function of time for 1 mg/cm 2 GP application; (B), Normalised
fluorescence intensity of tumour versus normal as a function of time for
2.5 mg/cm2 GP application.

1-3 h (Fig. 2). Hence the tumour to normal (T/N) ratio was
not found to be statistically significant. However, although
the overall fluorescence intensity for both tumour and normal
tissue was high for the earlier time points there was still
discrimination of the tumour. Cutaneous fluorescence in
remote distal regions was also found to be high indicating
that the S-ALA that is still circulating is continuing to induce
localised PpIX production in different parts of the anatomy.
Microscopic confocal images were obtained using the laser
scanning confocal microscope (LSMS 10). Only tumours with
and without the S-ALA treatment were compared, as this is a
xenograft. Fig. SA shows the PpIX micro-fluorescence in a
NPC/CNE-2 tumour. Fig. SB is the H&E counter-staining of
the same section. It was found that the S-ALA is well taken up
by the NPC/CNE-2 tumour.
Discussion
Human tumour xenografts on Balb/c nude mice were used as
a model to investigate the efficacy of the topical application
in terms of PpIX production of tumour cells in an in vivo
system. Intravenous administration of S-ALA for endogenous
porphyrin based PDD and PDT, has been the normal mode
of administration. The main drawback of intravenous
administration is that the circulating S-ALA causes extensive
cutaneous PpIX accumulation, and makes it necessary for the
patients to avoid light, as they would still be photosensitive.
Thus, there are merits for local S-ALA delivery via topical
applications. This delivery system can take many forms such
as rinses, gels or creams, which have to be constituted

Figure 5. (A), PpIX microscopic fluorescence of NPC/CNE-2 xenograft
(x20). (B), Haematoxylin and eosin staining of NPC/CNE-2 xenograft
(x20).

extemporaneously when, needed due to instability of S-ALA.
Patches prepared for this study can be made and stored in an
airtight container at room temperature for three to six months.
These patches also have muco-adhesive properties and can
be good candidates for use in the oral cavity PDD and PDT.
Oral rinses require the patient to continuously rinse for 20 min.
Hence oral rinses are not practical for routine clinical use.
Also the contact time for S-ALA on oral tissue is short with
the use of an oral rinse.
In our investigations, it was detected that the intravenous
S-ALA administration not only gives high fluorescence of
tumour but also that of normal tissues at the early time points
both 1 and 3 h post S-ALA administration. This is due to
considerable amounts of circulating S-ALA inducing local
PpIX (and not circulating PpIX). In most cases normal liver
and skin appeared to have high production levels of PpIX.
The TIN fluorescence ratio was found to be not significant
between 1.S-2 h. The fluorescence intensity pattern observed
when both the GP and PP patches applied were found to
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be superior to the intravenous administration. The T/N
fluorescence ratio is significantly high at 3 h following
topical PP or GP muco-adhesive patch application. Despite
the expected differences in the availability of 5-ALA in the
GP and PP patches, their in vivo performances did not show
significant differences. This indicates that the rate-limiting
step to 5-ALA delivery to the tumour tissue was the transdermal transport of the hydrophilic 5-ALA compound. In
conclusion, there was no difference between the two polymer
based patches. Apart from the difference in the intensity of
the fluorescence amongst the different concentrations, the
TIN fluorescence ratio was consistent in both the low and
high 5-ALA concentration patches at both 3 and 6 h.
Between the intravenous administration and the topical
application, the difference lies in the fact that there is low
systemic uptake in the topical application and therefore TIN
fluorescence ratio is larger and found to be statistically
significant with the topical patches.
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